Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

Safety and Efficacy of Exenatide in Combination with Insulin in Patients with Type 2 Diabetes Mellitus

(2013) Catherine Sheffield et al.   Endocrine Practice

Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes

(2012) Philip Levin et al.   CURRENT MEDICAL RESEARCH AND OPINION

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

(2012) J. H. DeVries et al.   DIABETES CARE

GLP-1 based therapies: differential effects on fasting and postprandial glucose

(2012) M.S. Fineman et al.   DIABETES OBESITY & METABOLISM

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)

(2012) Y. Seino et al.   DIABETES OBESITY & METABOLISM

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study

(2012) M. Wenten et al.   DIABETIC MEDICINE

Effects of Exenatide on Measures of  -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes

(2011) M. C. Bunck et al.   DIABETES CARE

Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*

(2011) K. Y. Thong et al.   DIABETES OBESITY & METABOLISM

A cohort study of acute pancreatitis in relation to exenatide use

(2011) D. D. Dore et al.   DIABETES OBESITY & METABOLISM

An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future

(2011) S. Madsbad et al.   DIABETES OBESITY & METABOLISM

GLP-1 receptor agonists today

(2011) Michel Marre et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics

(2011) Riccardo Perfetti   Diabetes Technology & Therapeutics

Liraglutide

(2011) Caroline M. Perry   DRUGS

Clinical Outcomes Using Long-Term Combination Therapy with Insulin Glargine and Exenatide in Patients with Type 2 Diabetes Mellitus

(2011) Philip Levin et al.   Endocrine Practice

Lixisenatide for type 2 diabetes mellitus

(2011) Mikkel Christensen et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

GLP-1 analogues and insulin: sound the wedding bells?

(2011) Michael A. Nauck et al.   Nature Reviews Endocrinology

Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction

(2011) Marcus Lind et al.   Primary Care Diabetes

Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy

(2011) Manjiri D. Pawaskar et al.   JOURNAL OF MEDICAL ECONOMICS

Glucagon-Like Peptide-1 Analog and Insulin Combination Therapy in the Management of Adults with Type 2 Diabetes Mellitus

(2010) Maria Tzefos et al.   ANNALS OF PHARMACOTHERAPY

Diabetes and risk of pancreatic cancer: a pooled analysis of three large case–control studies

(2010) Donghui Li et al.   CANCER CAUSES & CONTROL

The Cardiovascular Effects of GLP-1 Receptor Agonists

(2010) Theodore Okerson et al.   Cardiovascular Therapeutics

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

(2010) D. J. Drucker et al.   DIABETES CARE

Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis

(2010) R. Garg et al.   DIABETES CARE

Hypoglycemia, Diabetes, and Cardiovascular Events

(2010) C. V. Desouza et al.   DIABETES CARE

New Perspectives in Type 2 Diabetes, Cardiovascular Risk, and Treatment Goals

(2010) Carol H. Wysham   POSTGRADUATE MEDICINE

Exenatide therapy in insulin-treated type 2 diabetes and obesity

(2010) U. A. Nayak et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient setting

(2009) Nancy M. Yoon et al.   CLINICAL THERAPEUTICS

Treatment approach and HbA1ccontrol among US adults with type 2 diabetes: NHANES 1999–2004

(2009) Allison Hedley Dodd et al.   CURRENT MEDICAL RESEARCH AND OPINION

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

(2009) David D. Dore et al.   CURRENT MEDICAL RESEARCH AND OPINION

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE

Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study

(2009) R. A. Noel et al.   DIABETES CARE

Exenatide: a review from pharmacology to clinical practice

(2009) R. Gentilella et al.   DIABETES OBESITY & METABOLISM

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

(2008) Ralph A. DeFronzo et al.   CURRENT MEDICAL RESEARCH AND OPINION

The Barrier of Hypoglycemia in Diabetes

(2008) P. E. Cryer   DIABETES

Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine

(2008) M. Davies et al.   DIABETES OBESITY & METABOLISM

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

(2008) Helle Linnebjerg et al.   REGULATORY PEPTIDES